FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033936822> ?p ?o ?g. }

• W2033936822 endingPage "4307" @default.
• W2033936822 startingPage "4302" @default.
• W2033936822 abstract "A double-blind, placebo-controlled, four-way crossover study was conducted in 40 subjects to assess the effect of linezolid on corrected QT (QTc) interval prolongation. Time-matched, placebo-corrected QT intervals were determined predose and at 0.5, 1 (end of infusion), 2, 4, 8, 12, and 24 h after intravenous dosing of linezolid 600 and 1,200 mg. Oral moxifloxacin at 400 mg was used as an active control. The pharmacokinetic profile of linezolid was also evaluated. At each time point, the upper bound of the 90% confidence interval (CI) for placebo-corrected QTcF values (i.e., QTc values adjusted for ventricular rate using the correction methods of Fridericia) for linezolid 600 and 1,200-mg doses were <10 ms, which indicates an absence of clinically significant QTc prolongation. At 2 and 4 h after the moxifloxacin dose, corresponding to the population T(max), the lower bound of the two-sided 90% CI for QTcF when comparing moxifloxacin to placebo was >5 ms, indicating that the study was adequately sensitive to assess QTc prolongation. The pharmacokinetic profile of linezolid at 600 mg was consistent with previous observations. Systemic exposure to linezolid increased in a slightly more than dose-proportional manner at supratherapeutic doses, but the degree of nonlinearity was small. At a supratherapeutic single dose of 1,200 mg of linezolid, no treatment-related increase in adverse events was seen compared to 600 mg of linezolid, and no clinically meaningful effects on vital signs and safety laboratory evaluations were noted." @default.
• W2033936822 created "2016-06-24" @default.
• W2033936822 creator A5001422193 @default.
• W2033936822 creator A5003649836 @default.
• W2033936822 creator A5017481574 @default.
• W2033936822 creator A5039929913 @default.
• W2033936822 creator A5046819681 @default.
• W2033936822 creator A5052052135 @default.
• W2033936822 creator A5054965158 @default.
• W2033936822 date "2011-09-01" @default.
• W2033936822 modified "2023-10-14" @default.
• W2033936822 title "Lack of an Effect of Standard and Supratherapeutic Doses of Linezolid on QTc Interval Prolongation" @default.
• W2033936822 cites W1604250740 @default.
• W2033936822 cites W2020248903 @default.
• W2033936822 cites W2110370812 @default.
• W2033936822 cites W2127689004 @default.
• W2033936822 cites W2150324756 @default.
• W2033936822 cites W2152320283 @default.
• W2033936822 cites W2161181970 @default.
• W2033936822 doi "https://doi.org/10.1128/aac.01723-10" @default.
• W2033936822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3165302" @default.
• W2033936822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21709083" @default.
• W2033936822 hasPublicationYear "2011" @default.
• W2033936822 type Work @default.
• W2033936822 sameAs 2033936822 @default.
• W2033936822 citedByCount "8" @default.
• W2033936822 countsByYear W20339368222014 @default.
• W2033936822 countsByYear W20339368222016 @default.
• W2033936822 countsByYear W20339368222017 @default.
• W2033936822 countsByYear W20339368222019 @default.
• W2033936822 countsByYear W20339368222020 @default.
• W2033936822 countsByYear W20339368222023 @default.
• W2033936822 crossrefType "journal-article" @default.
• W2033936822 hasAuthorship W2033936822A5001422193 @default.
• W2033936822 hasAuthorship W2033936822A5003649836 @default.
• W2033936822 hasAuthorship W2033936822A5017481574 @default.
• W2033936822 hasAuthorship W2033936822A5039929913 @default.
• W2033936822 hasAuthorship W2033936822A5046819681 @default.
• W2033936822 hasAuthorship W2033936822A5052052135 @default.
• W2033936822 hasAuthorship W2033936822A5054965158 @default.
• W2033936822 hasBestOaLocation W20339368221 @default.
• W2033936822 hasConcept C112705442 @default.
• W2033936822 hasConcept C118441451 @default.
• W2033936822 hasConcept C126322002 @default.
• W2033936822 hasConcept C142724271 @default.
• W2033936822 hasConcept C185592680 @default.
• W2033936822 hasConcept C197934379 @default.
• W2033936822 hasConcept C204787440 @default.
• W2033936822 hasConcept C27081682 @default.
• W2033936822 hasConcept C2777288759 @default.
• W2033936822 hasConcept C2778836808 @default.
• W2033936822 hasConcept C2778980435 @default.
• W2033936822 hasConcept C2779489039 @default.
• W2033936822 hasConcept C2779703243 @default.
• W2033936822 hasConcept C2781414143 @default.
• W2033936822 hasConcept C42219234 @default.
• W2033936822 hasConcept C44249647 @default.
• W2033936822 hasConcept C501593827 @default.
• W2033936822 hasConcept C523546767 @default.
• W2033936822 hasConcept C54355233 @default.
• W2033936822 hasConcept C55493867 @default.
• W2033936822 hasConcept C71924100 @default.
• W2033936822 hasConcept C86803240 @default.
• W2033936822 hasConcept C87813604 @default.
• W2033936822 hasConcept C98274493 @default.
• W2033936822 hasConceptScore W2033936822C112705442 @default.
• W2033936822 hasConceptScore W2033936822C118441451 @default.
• W2033936822 hasConceptScore W2033936822C126322002 @default.
• W2033936822 hasConceptScore W2033936822C142724271 @default.
• W2033936822 hasConceptScore W2033936822C185592680 @default.
• W2033936822 hasConceptScore W2033936822C197934379 @default.
• W2033936822 hasConceptScore W2033936822C204787440 @default.
• W2033936822 hasConceptScore W2033936822C27081682 @default.
• W2033936822 hasConceptScore W2033936822C2777288759 @default.
• W2033936822 hasConceptScore W2033936822C2778836808 @default.
• W2033936822 hasConceptScore W2033936822C2778980435 @default.
• W2033936822 hasConceptScore W2033936822C2779489039 @default.
• W2033936822 hasConceptScore W2033936822C2779703243 @default.
• W2033936822 hasConceptScore W2033936822C2781414143 @default.
• W2033936822 hasConceptScore W2033936822C42219234 @default.
• W2033936822 hasConceptScore W2033936822C44249647 @default.
• W2033936822 hasConceptScore W2033936822C501593827 @default.
• W2033936822 hasConceptScore W2033936822C523546767 @default.
• W2033936822 hasConceptScore W2033936822C54355233 @default.
• W2033936822 hasConceptScore W2033936822C55493867 @default.
• W2033936822 hasConceptScore W2033936822C71924100 @default.
• W2033936822 hasConceptScore W2033936822C86803240 @default.
• W2033936822 hasConceptScore W2033936822C87813604 @default.
• W2033936822 hasConceptScore W2033936822C98274493 @default.
• W2033936822 hasIssue "9" @default.
• W2033936822 hasLocation W20339368221 @default.
• W2033936822 hasLocation W20339368222 @default.
• W2033936822 hasLocation W20339368223 @default.
• W2033936822 hasLocation W20339368224 @default.
• W2033936822 hasOpenAccess W2033936822 @default.
• W2033936822 hasPrimaryLocation W20339368221 @default.
• W2033936822 hasRelatedWork W1604467628 @default.
• W2033936822 hasRelatedWork W1966311188 @default.

• next